A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Recruiting now · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumors
In brief
The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
Key facts
- Study ID
- NCT06697197
- Run by
- Bristol-Myers Squibb
- People needed
- 413
- Starts
- 2025-02-17
- Expected to finish
- 2029-01-05
- Last updated by the study team
- 2026-02-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy measurable by RECIST v1.1, and have received, be refractory to, ineligible for, intolerant of, or refused existing therapy(ies) known to provide clinical benefit for the condition of the participant.
- Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place, inclusive, at the time of signing the ICF.
You may not qualify if…
- History of life threatening immune mediated toxicity related to prior T-cell agonist or checkpoint inhibitor therapy, except those that are unlikely to re-occur with standard countermeasures.
- Any significant acute or chronic medical illness which would interfere with study intervention or follow-up in the opinion of the investigator.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Where it is running
- Karolinska Universitetssjukhuset Solna — Solna, Stockholms Län [se-01], Sweden (enrolling)
- The Angeles Clinic and Research Institute - West Los Angeles Office — Los Angeles, California, United States (enrolling)
- University of California, Irvine (UCI) Health - UC Irvine Medical Center — Irvine, California, United States (enrolling)
- John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States (enrolling)
- Northwell Health/ RJ Zuckerberg Cancer Center — Lake Success, New York, United States (enrolling)
- Levine Cancer Institute — Charlotte, North Carolina, United States (enrolling)
- Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)
- UZ Gent — Ghent, Oost-Vlaanderen, Belgium (enrolling)
- Rigshospitalet — Copenhagen, Capital Region, Denmark (enrolling)
- Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone — Marseille, Bouches-du-Rhône, France (enrolling)
- Gustave Roussy — Villejuif, Paris, France (enrolling)
- General Hospital of Athens "Laiko" — Athens, Attikí, Greece (enrolling)
- Papageorgiou General Hospital of Thessaloniki — Thessaloniki, Thessaloníki, Greece (enrolling)
- Fondazione IRCCS Istituto Nazionale dei Tumori — Milan, Lombardy, Italy (enrolling)
- Istituto Clinico Humanitas — Rozzano, Milano, Italy (enrolling)
- Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) — Amsterdam, North Holland, Netherlands (enrolling)
- Erasmus Medisch Centrum — Rotterdam, Netherlands (enrolling)
- Hospital Universitari Vall d'Hebron — Barcelona, Barcelona [Barcelona], Spain (enrolling)
- Clinica Universidad de Navarra — Pamplona, Navarre, Spain (enrolling)
- Hospital Universitario HM Sanchinarro — Madrid, Spain (enrolling)
- Local Institution - 0008 — Aurora, Colorado, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.